Drug Interactions between amiodarone and M-M-R II
This report displays the potential drug interactions for the following 2 drugs:
- amiodarone
- M-M-R II (measles virus vaccine/mumps virus vaccine/rubella virus vaccine)
Interactions between your drugs
measles virus vaccine rubella virus vaccine
Applies to: M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine) and M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine)
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
measles virus vaccine mumps virus vaccine
Applies to: M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine) and M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine)
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
rubella virus vaccine mumps virus vaccine
Applies to: M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine) and M-M-R II (measles virus vaccine / mumps virus vaccine / rubella virus vaccine)
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
Drug and food/lifestyle interactions
amiodarone food/lifestyle
Applies to: amiodarone
GENERALLY AVOID: Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. In 11 nonsmoking, healthy volunteers, grapefruit juice (300 mL with drug administration, then 3 hours and 9 hours later) increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of amiodarone (17 mg/kg single dose) by 84% and 50%, respectively, compared to water. Formation of the pharmacologically active metabolite, N-desethylamiodarone (N-DEA), was completely inhibited. Clinically, this interaction can lead to altered efficacy of amiodarone, since antiarrhythmic properties of amiodarone and N-DEA appear to differ. In the study, mean increases in PR and QTc intervals of 17.9% and 11.3%, respectively, were observed 6 hours postdose with water, while increases of 10.2% and 3.3%, respectively, were observed after administration with grapefruit juice.
ADJUST DOSING INTERVAL: Food increases the rate and extent of absorption of amiodarone. The mechanism appears to involve the effect of food-induced physiologic changes on drug release from its formulation. In 30 healthy volunteers, administration of a single 600 mg dose of amiodarone following a high-fat meal resulted in a Cmax and AUC that were 3.8 and 2.4 times the respective values under fasting conditions. The time to reach peak plasma concentration (Tmax) was decreased by 37%, indicating an increased rate of absorption. Mean Cmax and AUC for the active metabolite, N-DEA, also increased by 32% and 55%, respectively, but there was no change in the Tmax.
MANAGEMENT: Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice. In addition, oral amiodarone should be administered consistently with regard to meals.
References (3)
- (2002) "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories
- Libersa CC, Brique SA, Motte KB, et al. (2000) "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol, 49, p. 373-8
- Meng X, Mojaverian P, Doedee M, Lin E, Weinryb I, Chiang ST, Kowey PR (2001) "Bioavailability of Amiodarone tablets administered with and without food in healthy subjects." Am J Cardiol, 87, p. 432-5
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.